Prognostic Value of Estimated Glucose Disposal Rate in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Figures

• 

  Fig. 1.. Study flowchart. NSTE-ACS, non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention; T1DM, Type 1 Diabetes mellitus; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; ALT, alanine transaminase; AST, aspartate transaminase; URL, upper reference limit; eGDR, estimated glucose disposal rate; WC, waist circumference; BMI, body mass index.

• 

  Fig. 2.. Kaplan-Meier survival analysis based on the tertiles of eGDR. (A) Kaplan-Meier survival curve analysis of the primary endpoint in the overall population for the three groups based on eGDRWC. (B) Kaplan-Meier survival curve analysis of the primary endpoint in diabetics for the three groups based on eGDRWC. (C) Kaplan-Meier survival curve analysis of the primary endpoint in non-diabetic cases for the three groups based on eGDRWC. (D) Kaplan-Meier survival curve analysis of the primary endpoint in the overall population for the three groups based on eGDRBMI. (E) Kaplan-Meier survival curve analysis of the primary endpoint for diabetics for the three groups based on eGDRBMI. (F) Kaplan-Meier survival curve analysis of the primary endpoint in non-diabetic cases for the three groups based on eGDRBMI. eGDR, estimated glucose disposal rate.

• 

  Fig. 3.. Restricted cubic smoothing for the risk of the primary endpoint based on eGDR𝐖𝐂. Adjustment was performed for Model 3. HR was assessed per 1-unit elevated of eGDRWC. eGDRWC, estimated glucose disposal rate calculated by waist circumference.

• 

  Fig. 4.. Subgroup analysis evaluating the robustness of eGDR𝐖𝐂 in predicting the risk of the primary endpoint. The analysis was adjusted for Model 3 except for variates applied for grouping. HR was evaluated by per 1-unit decrease of eGDRWC. OHA, oral hypoglycemic agents.